TG THERAPEUTICS
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Drug: Azercabtagene zapreleucel (azer-cel)
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06680037
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple SclerosisMultiple Sclerosis
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06433752
- Locations
- 🇵🇷
TG Therapeutics Investigational Trial Site, Guaynabo, Puerto Rico
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- Other: No intervention
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 728
- Registration Number
- NCT06433765
- Locations
- 🇺🇸
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina, United States
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Other: No intervention
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06143514
- Locations
- 🇺🇸
PROVIDE Virtual Research Coordination Center, Wilmington, North Carolina, United States
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05877963
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
🇺🇸TG Investigational Site, Farmington, Michigan, United States
🇺🇸TG Therapeutics Investigational Trial SiteCharlotte, Charlotte, North Carolina, United States
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Indolent LymphomaFollicular LymphomaDLBCLSLLMediastinal Large B-cell LymphomaCLLRichter's TransformationMarginal Zone LymphomaAggressive LymphomaMCL
- Interventions
- Biological: TG-1801Biological: Ublituximab
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04806035
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Houston, Texas, United States
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 1100
- Registration Number
- NCT04130997
- Locations
- 🇺🇦
TG Therapeutics Investigational Trial Site, Úzhgorod, Ukraine
🇭🇷TG Investigational Trial Site, Zagreb, Croatia
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04016805
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
- Conditions
- Follicular LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03828448
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Nashville, Tennessee, United States
Study of TG-1801 in Subjects With B-Cell Lymphoma
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03804996
- Locations
- 🇦🇺
TG Therapeutics Investigational Trial Site, Nedlands, Western Australia, Australia